157 related articles for article (PubMed ID: 17786950)
21. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid.
Johnson DR; Stebulis JA; Rossetti RG; Burstein SH; Zurier RB
J Cell Biochem; 2007 Jan; 100(1):184-90. PubMed ID: 16927387
[TBL] [Abstract][Full Text] [Related]
22. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
23. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
24. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
26. CpG oligonucleotides: novel regulators of osteoclast differentiation.
Zou W; Schwartz H; Endres S; Hartmann G; Bar-Shavit Z
FASEB J; 2002 Mar; 16(3):274-82. PubMed ID: 11874977
[TBL] [Abstract][Full Text] [Related]
27. RANKL-induced osteoclastogenesis in bone marrow-derived macrophages is suppressed by cisapride.
Park KR; Yun HM
Toxicology; 2019 Jun; 422():95-101. PubMed ID: 31150804
[TBL] [Abstract][Full Text] [Related]
28. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis.
Kim MH; Ryu SY; Bae MA; Choi JS; Min YK; Kim SH
Food Chem Toxicol; 2008 Nov; 46(11):3375-82. PubMed ID: 18786594
[TBL] [Abstract][Full Text] [Related]
29. Carbon Monoxide Inhibits Receptor Activator of NF-κB (RANKL)-Induced Osteoclastogenesis.
Tseng FJ; Chia WT; Wang CH; Shyu JF; Gou GH; Shui HA; Sytwu HK; Pan RY; Weng CF
Cell Physiol Biochem; 2015; 36(3):1250-8. PubMed ID: 26138885
[TBL] [Abstract][Full Text] [Related]
30. Reciprocal effects of Interferon-γ and IL-4 on differentiation to osteoclast-like cells by RANKL or LPS.
Hu Y; Ek-Rylander B; Wendel M; Andersson G
Oral Dis; 2014 Oct; 20(7):682-92. PubMed ID: 24118341
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism.
Zou W; Hakim I; Tschoep K; Endres S; Bar-Shavit Z
J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):70-83. PubMed ID: 11500955
[TBL] [Abstract][Full Text] [Related]
32. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid.
Rahman MM; Bhattacharya A; Fernandes G
J Cell Physiol; 2008 Jan; 214(1):201-9. PubMed ID: 17929247
[TBL] [Abstract][Full Text] [Related]
33. TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression.
Tokunaga T; Mokuda S; Kohno H; Yukawa K; Kuranobu T; Oi K; Yoshida Y; Hirata S; Sugiyama E
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991837
[TBL] [Abstract][Full Text] [Related]
34. The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression.
Fava RA; Elliott S; Raymond L; Mollmark J; Hays E; Honda T; Gribble GW; Sporn MB; Vincenti MP
J Rheumatol; 2007 May; 34(5):1058-68. PubMed ID: 17361985
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
36. Expression and role of mannose receptor/terminal high-mannose type oligosaccharide on osteoclast precursors during osteoclast formation.
Morishima S; Morita I; Tokushima T; Kawashima H; Miyasaka M; Omura K; Murota S
J Endocrinol; 2003 Feb; 176(2):285-92. PubMed ID: 12553877
[TBL] [Abstract][Full Text] [Related]
37. Protocatechuic acid inhibits osteoclast differentiation and stimulates apoptosis in mature osteoclasts.
Wu YX; Wu TY; Xu BB; Xu XY; Chen HG; Li XY; Wang G
Biomed Pharmacother; 2016 Aug; 82():399-405. PubMed ID: 27470378
[TBL] [Abstract][Full Text] [Related]
38. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
40. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
